Characterizing AutoReactive IgA Molecularly to Block Arthritis
The project explores IgA autoantibodies as potential biomarkers for disease outcomes and IgA-Fc-receptor therapy
The project focuses on investigating the role of IgA autoantibodies in the development of rheumatoid arthritis (RA) and their potential as biomarkers for disease severity and treatment response. This collaborative effort involves a newly established public-private partnership, combining the expertise of academic researchers and a private sector partner. The project aims to explore how these autoantibodies, particularly in their dimeric form, contribute to RA pathogenesis and whether blocking the IgA receptor could provide a new therapeutic option for patients who do not respond to existing treatments.
Rheumatoid arthritis is a chronic autoimmune disease that affects approximately 1% of the global population, with a higher incidence among women. RA causes significant disability, pain, and joint damage, leading to a reduced quality of life for affected individuals. The socio-economic burden of RA is substantial, with direct medical costs and productivity losses accounting for billions of dollars annually. Despite advances in treatment, RA remains incurable, and current therapies do not work for all patients, highlighting the urgent need for new, innovative treatment options to improve outcomes for these individuals.
The project’s innovative approach focuses on understanding the molecular mechanisms of RA, particularly the involvement of IgA autoantibodies in disease progression. By studying how these antibodies interact with immune receptors, the project aims to develop targeted therapies that block the IgA receptor. This strategy could offer a novel treatment for patients with therapy-resistant RA, addressing a critical gap in current care and potentially improving the effectiveness of RA treatments for a broader range of patients.
The project’s deliverables include the identification of key characteristics of IgA autoantibodies associated with disease severity, as well as the development of a new therapeutic approach targeting the IgA receptor. If successful, the research could lead to a breakthrough in RA treatment, offering a new option for patients who have limited alternatives. Additionally, the project will provide deeper insights into the role of autoantibodies in autoimmune diseases, laying the groundwork for future advancements in treatment.
Andere projecten
In elk PPS-project werken kennisinstellingen, bedrijven en zorgpartijen samen aan een concrete gezondheidsvraag. Bekijk het volledige projectoverzicht.
Bekijk de programma’s
Binnen onze programma’s werken bedrijven, kennisinstellingen en regionale partners samen aan innovaties die bijdragen aan betere gezondheid en zorg.
Bekijk de partnerschappen
Strategische publiek-private partnerschappen (PPP's) zijn meerjarige samenwerkingen tussen bedrijven, kennisinstellingen en andere partijen.
Hoe kunnen we je helpen?
Heb je een vraag of wil je meer weten over Health Holland? We brengen je graag in contact met de juiste mensen, kennis en mogelijkheden om gezondheidsinnovatie te versnellen.
We hebben uw bericht ontvangen
We nemen binnen 3 tot 4 werkdagen contact met je op. Is je vraag dringend? Neem dan gerust direct contact met ons op. Hieronder zie je de contactoptie die het beste past bij je onderwerp.
Opnieuw beginnen
Er ging iets mis bij het versturen van het formulier. Probeer het opnieuw.